Capricor Therapeutics Inc (CAPR) – it’s time to buy. Check out key Indicators

In yesterday’s Wall Street session, Capricor Therapeutics Inc (NASDAQ:CAPR) shares traded at $18.49, down -9.85% from the previous session.

CAPR stock price is now 111.84% away from the 50-day moving average and 208.75% away from the 200-day moving average. The market capitalization of the company currently stands at $601.66M.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

With the price target of $14, Oppenheimer recently initiated with Outperform rating for Capricor Therapeutics Inc (NASDAQ: CAPR). On January 05, 2024, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $8, while ‘Ladenburg Thalmann’ rates the stock as ‘Buy’

In other news, Nippon Shinyaku Co Ltd, 10% Owner bought 2,798,507 shares of the company’s stock on Sep 20 ’24. The stock was bought for $14,999,998 at an average price of $5.36. Upon completion of the transaction, the 10% Owner now directly owns 7,090,351 shares in the company, valued at $131.1 million. A total of 16.78% of the company’s stock is owned by insiders.

During the past 12 months, Capricor Therapeutics Inc has had a low of $2.68 and a high of $23.40. As of last week, the company has a debt-to-equity ratio of 0.45, a current ratio of 1.37, and a quick ratio of 1.37. The fifty day moving average price for CAPR is $8.7286 and a two-hundred day moving average price translates $5.98875 for the stock.

The latest earnings results from Capricor Therapeutics Inc (NASDAQ: CAPR) was released for 2024-06-30. The net profit margin was -102.93% and return on equity was -392.69% for CAPR. The company reported revenue of $3.97 million for the quarter, compared to $3.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.35 percent.

Related Posts